Epitope blocking: Positive and negative effects on the biodistribution of 125I-Labeled anti-tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen

Japanese Journal of Cancer Research

Volumn 89, Issue 4, 1998, Pages 436-444

  Kobayashi, Hisataka ^a   Sun, Bao Fu ^a   Han, Eui Sik ^a   Kim, Meyoung Kon ^a   Le, Nhat ^a   Wang, Qing Cheng ^b   Nelson, David L ^c   Pastan, Ira ^b   Waldmann, Thomas A ^c   Paik, Chang H ^a   Carrasquillo, Jorge A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Epitope; Fv fragment; Iodine 125; Monoclonal antibody; Radioimmunodetection

Indexed keywords

DISULFIDE; EPITOPE; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR; IODINE 125; MONOCLONAL ANTIBODY; RECEPTOR SUBUNIT;

ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; TUMOR XENOGRAFT;

EID: 15444358532     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00582.x     Document Type: Article

References (51)

1. Mach, J. P., Buchegger, F., Forni, M., Ritschard, J., Berche, C., Lumbroso, J.-D., Schreyer, M., Girardet, C., Accolla, R. S. and Carrel, S. Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol. Today, 2, 239-249 (1981).
2. Larson, S. M. Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. Cancer Res., 50, 892s-898s (1990).
3. Goldenberg, D. M. and Larson, S. M. Radioimmunodetection in cancer identification. J. Nucl. Med., 33, 803-814 (1992).
4. Carrasquillo, J. A. Radioimmunotherapy of leukemia and lymphoma. In "Principles of Nuclear Medicine." 2nd Ed., ed. H. Wagner, pp. 1117-1132 (1996). W.B. Saunders and Co., Philadelphia.
5. Pimm, M. V. Circulating antigen: bad or good for immunoscintigraphy? Nucl. Med. Biol., 22, 137-145 (1995).
6. Douillard, J. Y., Chatal, J. F., Saccavini, J. C., Curtet, C., Kremer, M., Peuvrel, P. and Koprowski, H. Pharmacokinetic study of radiolabeled anti-colorectal carcinoma monoclonal antibodies in tumor-bearing nude mice. Eur. J. Nucl. Med., 11, 107-113 (1985).
7. 111I-labelled F(ab′)2 fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts. Eur. J. Nucl. Med., 18, 339-345 (1991).
8. Watanabe, Y., Endo, K., Koizumi, M., Kawamura, Y., Saga, T., Sakahara, H., Kuroki, M., Matsuoka, Y. and Konishi, J. Effect of tumor mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice. Cancer Res., 49, 2884-2889 (1989).
9. Pimm, M. V., Durrant, L. G. and Baldwin, R. W. Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour: nude mouse xenograft model. Eur. J. Cancer Clin. Oncol., 25, 1325-1332 (1989).
10. Kobayashi, H., Sakahara, H., Saga, T., Hosono, M., Shirato, M., Kanda, H., Ishibashi, K., Watanabe, T., Endo, K., Ishiwata, I. and Konishi, J. A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer. Cancer Immunol. Immunother., 37, 143-149 (1993).
11. Hagan, P. L., Halpern, S. E., Chen, A., Krishnan, L., Frincke, J., Bartholomew, R. M., David, G. S. and Carlo, D. In vivo kinetics of radiolabeled monoclonal anti-CEA antibodies in animal models. J. Nucl. Med., 26. 1418-1423 (1985).
12. 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografts. Cancer Res., 49, 1587-1594 (1989).
13. Duewell, S., Horst, W. and Westera, G. Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co-112) xenografted in the nude mouse. Dependence on tumor size and injected dose. Cancer Immunol Immunother., 23, 101-106 (1986).
14. Carrasquillo, J. A., Sugarbaker, P., Colcher, D., Reynolds, J. C., Esteban, J., Bryant, G., Keenan, A. M., Perentesis, P., Yokoyama, K., Simpson, D. E., Ferroni, P., Farkas, R., Schlom, J. and Larson, S. M. Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. J. Nucl. Med., 29, 1022-1030 (1988).
15. Colcher, D., Esteban, J. M., Carrasquillo, J. A., Sugarbaker, P., Reynolds, J. C., Bryant, G., Larson, S. M. and Schlom, J. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res., 47, 1185-1189 (1987).
16. Davis, Q., Perkins, A. C., Symonds, E. M., Frier, M., Wastie, M. L., van Hof, A. C., Ross, J. C., den Hollander, W., Sopwith, M. and Kenemans, P. Immunoseintigraphy of ovarian cancer using a CDR grafted antibody (hCTM01): first clinical results (abstract). Nukleannedizin, 33, 62 (1994).
17. 111indium-labelled monoclonal antibody CTM01 (hCTM01) in ovarian cancer patients (abstract). Nuklearmedizin, 33, 60 (1994).
18. Yoo, T. M., Chang, H. K., Choi, C. W., Webber, K. O., Le, N., Sood, V. K., Carrasquillo, J. A., Eckelman, W. C., Pastan, I. and Paik, C. H. Radiolabeling of anti-Tac disulfide stabilized Fv fragment with Tc-99m and its evaluation in athymic mice with tumor xenografts. J. Nucl. Med., 38, 294-300 (1997).
19. Kay, N. E., Burton, J., Wagner, D. and Nelson, D. L. The malignant B cells from B-chronic lymphocytic leukemia patients release Tac-soluble interleukin-2 receptors. Blood, 72, 447-450 (1988).
20. Richards, J., Mick, R., Latta, J. M., Daly, K., Ratain, M. J., Vardiman, J. W. and Colomb, H. M. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood, 76, 1941-1945 (1990).
21. Motoi, T., Uchiyama, T., Hori, T., Itoh, K., Uchino, H. and Ueda, R. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood, 74, 1052-1057 (1989).
22. Ambrosetti, A., Semenzato, G., Prior, M., Chilosi, M., Vinunte, F., Vincenzi, C., Zanotti, R., Trentin, L., Portuese, A., Menestrina, F., Perona, G., Agostini, C. and Todeschini, G. Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. Br. J. Haematol., 73, 181-186 (1989).
23. Wolf, R. E. and Breisford, W. G. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum., 31, 729-735 (1988).
24. Nakanishi, K., Taniguchi, Y. and Ohta, Y. Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease. Acta Endocrinol. (Copenh.), 125, 253-258 (1991).
25. Anasetti, C., Hansen, J. A., Waldmann, T. A., Appelbaum, F. R., Davis, J., Deeg, H. J., Doney, K., Martin, P. J., Nash, R., Storb, R., Sullivan, K. M., Witherspoon, R. P., Binger, M.-H., Chizzonite, R., Hakimi, J., Mould, D., Satoh, H. and Light, S. E. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood, 84, 1320-1327 (1994).
26. Waldmann, T. A. Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma. J. Natl. Cancer Inst., 81, 914-923 (1989).
27. Uchiyama, T., Broder, S. and Waldmann, T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol., 126, 1393-1397 (1981).
28. Depper, J. M., Leonard, W. J., Kronke, M., Noguchi, P. D., Cunningham, R. E., Waldmann, T. A. and Greene, W. C. Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J. Immnnol., 133, 3054-3061 (1984).
29. Waldmann, T. A., White, J. D., Carrasquillo, J. A., Reynolds, J. C., Paik, C. H., Gansow, O. A., Brechbiel, M. W., Jaffe, E. S., Fleisher, T. A., Goldman, C. K., Top, L. E., Bamtbrd, R., Zaknoen, S., Roessler, E., Kasten-Sportes, C., England, R., Litou, H., Johnson, J. A., Jackson-White, T., Manns, A., Hanchard, B., Junghans, R. P. and Nelson, D. L. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood, 86, 4063-4075 (1995).
30. Kirkman, R. L., Shapiro, M. E., Carpenter, C. B., McKay, D. B., Milford, E. L., Ramos, E. L., Tilney, N. L., Waldmann, T. A., Zimmerman, C. E. and Strom, T. B. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation, 51, 107-113 (1991).
31. Cooper, M. M., Robbins, R. C., Goldman, C. K., Mirzadeh, S., Brechbiel, M. W., Stone, C. D., Gansow, O. A., Clark, R. E. and Waldmann, T. A. Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation [see comments]. Transplantation, 50, 760-765 (1990).
32. Parenteau, G. L., Dirbas, F. M., Gurmestani, K., Brechbiel, M. W., Bukowski, M. A., Goldman, C. K., Clark, R., Gansow, O. A. and Waldmann, T. A. Prolongation of graft survival in primate allogratt transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colonystimulating factor. Transplantation, 54, 963-968 (1992).
33. Webber, K. O., Reiter, Y., Brinkmann, U., Kreitman, R. and Pastan, I. Preparation and characterization of a disulfide-stahilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol. Immunol., 32, 249-258 (1995).
34. Brinkmann, U., Chowdhury, P. S., Roscoe, D. M. and Pastan, I. Phage display of disulfide-stabilized Fv fragments. J. Immunol. Methods, 182, 41-50 (1995).
35. 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts. Cancer Res., 55, 5323-5329 (1995).
36. 99mTc-labeled anti-Tac dsFv. Cancer Res., 56, 3788-3795 (1996).
37. 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the a subunit of interleukin-2 receptor in the circulation with preinjected humanized anti-Tac IgG. Cancer Res., 57, 1955-1961 (1997).
38. Yokota, T., Milenic, D. E., Whitlow, M., Wood, J. F., Hubert, S. L. and Schlom, J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res., 53, 3776-3783 (1993).
39. Yokota, T., Milenic, D. E., Whitlow, M. and Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res., 52, 3402-3408 (1992).
40. Rubin, L. A., Kurman, C. C., Biddison, W. E., Goldman, N. D. and Nelson, D. L. A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma, 4, 91-102 (1985).
41. Robb, R. J., Rusk, C. M. and Keeper, M. P. Structure-function relationships for the interleukin 2 receptor: location of ligand and antibody binding sites on the Tac receptor chain by mutational analysis. Proc. Natl. Acad. Sci. USA, 85, 5654-5658 (1988).
42. Uchiyama, T., Nelson, D. L., Fleisher, T. A. and Waldmann, T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J. Immnol., 126, 1398-1403 (1981).
43. Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P. and Waldmann, T. A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA, 86, 10029-10033 (1989).
44. Fraker, P. J. and Speck, J. C., Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril. Biochem. Biophys. Res. Commun., 80, 849-857 (1978).
45. 131I-labelled human growth hormone of high specific radioactivity. Biochem. J., 89, 114-123 (1963).
46. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J. and Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods. 72, 77-89 (1984).
47. 212Bi-anti-Tac. Cancer Res., 54, 4362-4370 (1994).
48. Junghans, R. P. and Waldmann, T. A. Metabolism of Tac (IL2Rα): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J. Exp. Med., 183, 1587-1602 (1996).
49. Berson, S. A. and Yalow, R. S. Insulin in blood and insulin antibodies. Am. J. Med., 40, 676-690 (1966).
50. Jacques, Y., Le Mauff, B., Boeffard, F., Godard, A. and Soulillou, J. P. A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity. J. Immunol., 139, 2308-2316 (1987).
51. Finkelman, F. D., Madden, K. B., Morris, S. C., Holmes, J. M., Boiani, N., Katona, I. M. and Maliszewski, C. R. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol., 151, 1235-1244 (1993).